CARISMA Therapeutics
Manufacturing · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3675 Market St Ste 200, Philadelphia, Pe...Phone Number
(267) 491-6422Website
www.carismatx.comRevenue
$10.8 MillionStock Symbol
CARMIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About CARISMA Therapeutics
Carisma Therapeutics Inc. is a biopharmaceutical company dedicated to developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors. Carisma Therapeutics is headquartered in Philadelphia, PA.Explore more
CARISMA Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CARISMA Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on CARISMA Therapeutics recently announced quarterly report
Check out if CARISMA Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once CARISMA Therapeutics has new funding data
CARISMA Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if CARISMA Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at CARISMA Therapeutics
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when CARISMA Therapeutics launches new products
Check if CARISMA Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined CARISMA Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to CARISMA Therapeutics
Compare insights from companies similar to CARISMA Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
CARISMA Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
CARISMA Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about CARISMA Therapeutics.
CARISMA Therapeutics financials insights
Gather financial insights about CARISMA Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$53M
2021
Series B
$59M
CARISMA Therapeutics Tech Stack
A closer look at the technologies used by CARISMA Therapeutics
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Left Company
Executive Move
Executive Moves, Left Company
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
CARISMA Therapeutics News & Media
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Carisma Therapeutics Inc. (NASDAQ: CARM)
NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Carisma Therapeutics Inc. (NASDAQ: CARM) related to its to OrthoCellix, Inc. Upon completion of the proposed transactioCarisma Therapeutics, OrthoCellix enter definitive merger agreement
Carisma Therapeutics (CARM) and OrthoCellix, a wholly-owned subsidiary of Ocugen (OCGN), announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the development of OrthoCellix’s NeoCart technology for the treatment of knee articular cartilage defects and plans to initiate a U.S. Food and Drug Administration-endorsed Phase 3 clinical trial for NeoCart. OrthoCellix is developing NeoCart as an autolCARM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Carisma Therapeutics Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Carisma Therapeutics Inc. (NASDAQ: CARM) and OrthoCellix, Inc. is fair to Carisma shareholders. Upon completion of the proposed transaction, existing Carisma shareholders are expected to own approximately 10% of the combined company. Halper Sadeh encourages Carisma shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary HalperMerger Creates $25M Backed Phase 3 Knee Cartilage Therapy Company | OCGN Stock News
Phase 3-ready NeoCart® technology targets knee cartilage repair with breakthrough cell therapy approach. $25M financing secured for clinical trials. Get details.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CARISMA Therapeutics
Sign Up For FreeTo access detailed company insights
Carisma Therapeutics Inc. is a biopharmaceutical company dedicated to developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylva... Read More
